FIELD: medicine.
SUBSTANCE: present invention relates to an anti-CD19 antibody or its antigen-binding fragment, an isolated polynucleotide sequence encoding them, an expression vector containing the isolated polynucleotide, a host cell for obtaining an antibody or its antigen-binding fragment, a method for expressing an antibody or its antigen-binding fragment, an antibody-drug conjugate, a pharmaceutical composition for the treatment of a CD19-bound disease or condition, a method for treating a CD19-related disease or pathological condition, a chimeric antigenic receptor, a nucleic acid sequence molecule, an expression vector containing a nucleic acid sequence, an isolated T cell, a method for stimulating the T cell immune response, a kit for detecting the presence or amount of CD19 in a sample or for diagnosing a CD19-related disease or condition in an individual.
EFFECT: expansion of the range of solutions for treating CD19.
19 cl, 7 ex, 14 dwg, 14 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
